U.S., Aug. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07142811) titled 'A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection' on Aug. 19.
Brief Summary: A Study to Evaluate Tobevibart+Elebsiran versus Bulevirtide in Chronic HDV Infection
Study Start Date: Aug. 05
Study Type: INTERVENTIONAL
Condition:
Viral Hepatitis
Intervention:
DRUG: Tobevibart
Tobevibart administered by subcutaneous injection
DRUG: Elebsiran
Elebsiran administered by subcutaneous injection
DRUG: Bulevirtide
Bulevirtide administered by subcutaneous injection
Recruitment Status: RECRUITING
Sponsor: Vir Biotechnology, Inc.
Published by HT Digital Content Services with permission from Health ...